Formulation: A solid
Formal Name: (6R)-1,6-dihydro-N2,N2,6-trimethyl-1,3,5-triazine-2,4-diamine, hydrochloride
Purity: ≥95%
Formula Markup: C6H13N5 • XHCl
Formula Weight: 155,2
Shelf life (days): 1460
CAS Number: 775351-61-6
Notes: Imeglimin is an anti-hyperglycemic compound.{69519} It inhibits high-glucose- or tert-butyl hydroperoxide-induced cell death in HMEC-1 endothelial cells when used at a concentration of 100 µM. Imeglimin (100 µM) reduces tert-butyl hydroperoxide-induced cytochrome c levels, as well as mitochondrial membrane permeability without affecting mitochondrial respiration, in HMEC-1 cells. It decreases plasma glucose levels and increases plasma insulin levels in a rat model of high-fat diet-induced obesity when administered at a dose of 150 mg/kg.{69520} Imeglimin (100 mg/kg) also reduces colonic balloon-induced pain-related muscle contractions in rats.{69521} In vivo, imeglimin (100 mg/kg) reduces colonic hyperpermeability in a rat model of LPS-induced irritable bowel syndrome (IBS), an effect that can be reversed by the AMP-activated protein kinase (AMPK) inhibitor compound C (dorsomorphin; Item Nos. 11967 / 21207) or the peroxisome proliferator-activated receptor γ (PPARγ) antagonist GW 9662 (Item No. 70785). Formulations containing imeglimin have been used in the treatment of type 2 diabetes.
English
Deutsch
